
RealRate

PHARMACEUTICAL 2022

Biohaven Pharmaceutical Holding Co Ltd.



Rank 354 of 475



RealRate

PHARMACEUTICAL 2022

Biohaven Pharmaceutical Holding Co Ltd.



Rank 354 of 475

The relative strengths and weaknesses of Biohaven Pharmaceutical Holding Co Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biohaven Pharmaceutical Holding Co Ltd. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 66% points. The greatest weakness of Biohaven Pharmaceutical Holding Co Ltd. is the variable Assets, Current, reducing the Economic Capital Ratio by 156% points.

The company's Economic Capital Ratio, given in the ranking table, is -296%, being 19% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	876,254
Cost of Goods Sold	91,664
Intangible Assets	56,438
Liabilities, Current	534,202
Liabilities, Non-Current	12,236
Other Assets	129,830
Other Compr. Net Income	1,423
Other Expenses	5,073
Other Liabilities	1,213,783
Other Net Income	-139,279
Property and Equipment	14,690
Research and Development	361,340
Revenues	462,509
Selling, General and Administrative Expense	713,549

Output Variable	Value in 1000 USD
Assets	1,077,212
Liabilities	1,760,221
Expenses	1,171,626
Stockholders Equity	-683,009
Net Income	-848,396
Comprehensive Net Income	-847,684
Economic Capital Ratio	-296%